Industry & Policy News

[Ossium Health, Inc. (Business Wire)] Ossium Health, Inc. announced that the CIRM has awarded the company a $3.46M Clinical Stage Research Program grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory GVHD.

[Fierce Biotech] The nine-year wait for new clinical data on Promore Pharma’s ensereptide has ended in disaster, with the failure of the polypeptide to reduce scarring in a midphase trial wounding the biotech’s share price.

[Arbutus Biopharma Corp.] Arbutus Biopharma Corporation announced that they were notified via verbal communication from the US FDA that the AB-101 Investigational New Drug (IND) application has been placed on clinical hold.

[American Liver Foundations] On behalf of nearly 100 million Americans affected by liver disease, Lorraine Stiehl, Chief Executive Officer of the American Liver Foundation, applaud the reintroduction of the Living Donor Protection Act of 2023, which will help protect living organ donors from discrimination in insurance and ensure living donors can take time off for organ donation and recovery under the Family and Medical Leave Act.

[Mount Sinai] The Icahn School of Medicine at Mount Sinai announced the creation of the Institute for Regenerative Medicine to foster innovative research into new pathways to cure a host of diseases from leukemia to Alzheimer’s disease, breast cancer, and airway diseases.

[Western University] The $4-million endowed chair, funded in partnership with Western and London Health Sciences Foundation, will focus on driving innovation in research and transforming how cancers of the urinary tract and the male reproductive system are diagnosed and treated.